Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial

Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial

Abstract Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not pe...

Full description

Bibliographic Details
Main Authors: Edward L. Snyder, Michael E. Sekela, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Alesia Kaplan, Robertson D. Davenport, Tina S. Ipe, Peyman Benharash, Ileana Lopez-Plaza, Richard R. Gammon, Patrick Sadler, John P. Pitman, Kathy Liu, Stanley Bentow, Laurence Corash, Nina Mufti, Jeanne Varrone, Richard J. Benjamin, for the ReCePI study group
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Trials
Subjects:
Amustaline/GSH
INTERCEPT
Pathogen reduction
Transfusion-transmitted infections
Randomized controlled trial
Cardiac surgery
Online Access:https://doi.org/10.1186/s13063-023-07831-x

Internet

https://doi.org/10.1186/s13063-023-07831-x

Similar Items